3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Renal Cell
36
Kidney Neoplasms
9
Neoplasm Metastasis
7
Neoplasms
6
Melanoma
5
Colorectal Neoplasms
5
Glioblastoma
4
Carcinoma, Hepatocellular
4
Recurrence
3
Clear-cell metastatic renal cell carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Liver Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Adenoid Cystic
2
cT2a N0NxM0 Renal Tumor
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Solitary Fibrous Tumors
1
Solid Malignancies
1
Skin Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Salivary Gland Neoplasms
1
Relapsed Pediatric Solid Tumor
1
Radiation Therapy
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Ovarian Neoplasms
1
Interventions
Cisplatin
28
Pemetrexed
24
pembrolizumab
12
Nivolumab
10
Carboplatin
9
atezolizumab
7
Gemcitabine
7
Cyclophosphamide
7
durvalumab
6
Drug Therapy
6
sodium thiosulfate
5
Radiotherapy, Intensity-Modulated
5
tremelimumab
4
aldesleukin
4
Radiotherapy
4
Interleukin-2
4
sargramostim
3
Vinorelbine
3
Platinum
3
Photochemotherapy
3
Ipilimumab
3
Doxorubicin
3
Dihematoporphyrin Ether
3
Chemotherapy, Adjuvant
3
Cerebral Decortication
3
vatalanib
2
regorafenib
2
niraparib
2
lenvatinib
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma, Malignant
×
Axitinib
×
Clear all
NCT01211275
2017-02-28
N08CPA
The Netherlands Cancer Institute
Phase 1/2
Completed
32 enrolled